| answer text |
<p>The Department has made no such assessment. The National Institute for Health and
Care Excellence (NICE) reviewed its guidelines portfolio in May 2023 to identify topics
that it thinks will add the most value to the health and care system, considering
key factors such as clinical benefit, cost effectiveness, the potential to increase
productivity and support workforce issues and the potential to address health inequalities.
As a result, NICE identified several topics, including the guidance on haemochromatosis,
where work will stop for the time being to allow focus on key priorities. NICE consulted
on the scope for the guideline on haemochromatosis in January 2023 but has not published
the final scope.</p><p>These topics will be reconsidered by NICE’s new Prioritisation
Board that is being established by its Chief Medical Officer, and as work to establish
the prioritisation board progresses, more information on timescales will become available.
NICE will make further information available on its website once topics have been
reprioritised.</p>
|
|
